Endeavouring to Improve Glioblastoma Multiforme Patient Prognosis – A Literature Review of Biomarkers and Novel Therapeutic Approaches

Glioblastoma Multiforme (GBM) patients typically deteriorate at a rapid rate, and survive an average of 15 months from diagnosis – despite clinical intervention with the current approach of maximal surgical resection and adjuvant chemoradiotherapy. Tumour recurrence and treatment resistance remain inevitable with this standard treatment protocol, and therefore, we must endeavour to investigate more efficacious alternatives which offer better patients better prognosis and quality of life.

Cefepime-induced Cotard syndrome: a case report

Cotard syndrome features nihilistic delusions about one’s body or existence and is typically related to severe depression though is rarely associated with medical or neurological insults. The patient was a 62-year-old male with no past psychiatric history and a past medical history of congestive heart failure and consequent renal failure who presented for scheduled heart and kidney transplantation. He was started on routine post-transplant ganciclovir and steroids. Due to postoperative hypotension, empiric cefepime was initiated to cover for septic shock. One week postoperatively, the patient stated “I am dead.”